Skip to main content

Dysmenorrhea

9
Pipeline Programs
10
Companies
18
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
2
2
3
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Pfizer
FELDENEApproved
piroxicam
Pfizer
oral1982
29K Part D

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
piroxicamPhase 41 trial
ERB-041Phase 22 trials
Active Trials
NCT00318500Completed150Est. Dec 2006
NCT00110487Completed200Est. Dec 2006
NCT00649415Completed154Est. Jul 2003
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Naproxen Sodium 550mgPhase 41 trial
Active Trials
NCT06861920Recruiting600Est. Jul 2030
Bayer
BayerLEVERKUSEN, Germany
6 programs
2
2
EE20/DRSPPhase 31 trial
EE20/DRSPPhase 31 trial
DRSP 3 mg/EE 20 µgPhase 2/31 trial
SH T04740BPhase 2/31 trial
EE20/DRSPN/A1 trial
+1 more programs
Active Trials
NCT01375998Completed3,273Est. Mar 2018
NCT04607382Completed397Est. Jun 2021
NCT01031459Completed176Est. Dec 2010
+4 more trials
Juniper Biosciences
Juniper BiosciencesNJ - Bridgewater
1 program
1
LidocainePhase 21 trial
Active Trials
NCT00651313Completed81Est. Aug 2008
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Cooperative Adenomyosis NetworkN/A1 trial
Active Trials
NCT03230994Unknown5,000Est. Dec 2020
Enterprise Therapeutics
1 program
Nanoone Woman UnderwearN/A1 trial
Active Trials
NCT01449305Completed44Est. Jun 2012
Innovation Pharmaceuticals
1 program
Warm Palace Analgesic Point StickerN/A1 trial
Active Trials
NCT05815654Unknown200Est. Feb 2024
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Meloxicam 7.5 mgPHASE_21 trial
Active Trials
NCT02183025Completed337
Teva
TevaIsrael - Petach Tikva
1 program
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tabletsPHASE_22 trials
Active Trials
NCT00196313Completed95Est. Oct 2008
NCT00196365Completed97Est. Jul 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Human BioSciencesNaproxen Sodium 550mg
Pfizerpiroxicam
BayerEE20/DRSP
BayerEE20/DRSP
Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
BayerSH T04740B
BayerDRSP 3 mg/EE 20 µg
Juniper BiosciencesLidocaine
PfizerERB-041
Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
PfizerERB-041
Boehringer IngelheimMeloxicam 7.5 mg
Innovation PharmaceuticalsWarm Palace Analgesic Point Sticker
BayerLEP
UNION therapeuticsCooperative Adenomyosis Network

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 11,689 patients across 18 trials

NCT06861920Human BioSciencesNaproxen Sodium 550mg

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Start: Apr 2025Est. completion: Jul 2030600 patients
Phase 4Recruiting

A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

Start: Jan 2003Est. completion: Jul 2003154 patients
Phase 4Completed

To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Start: Jan 2016Est. completion: Oct 20170
Phase 3Withdrawn

Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Start: Jul 2013Est. completion: Aug 2015216 patients
Phase 3Completed
NCT00196365Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Start: Jan 2005Est. completion: Jul 200797 patients
Phase 3Completed

SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

Start: Jul 2007Est. completion: Jan 2009249 patients
Phase 2/3Completed
NCT00461305BayerDRSP 3 mg/EE 20 µg

Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea

Start: Feb 2007Est. completion: Aug 2009420 patients
Phase 2/3Completed

Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)

Start: Aug 2007Est. completion: Aug 200881 patients
Phase 2Completed

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

Start: May 2006Est. completion: Dec 2006150 patients
Phase 2Completed
NCT00196313Tevalevonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Start: May 2005Est. completion: Oct 200895 patients
Phase 2Completed

Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

Start: Jan 2005Est. completion: Dec 2006200 patients
Phase 2Completed

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Start: Jan 1998337 patients
Phase 2Completed
NCT05815654Innovation PharmaceuticalsWarm Palace Analgesic Point Sticker

Research and Development of WPAPS Based on the Modern Technology of Traditional Chinese Medicine

Start: Dec 2022Est. completion: Feb 2024200 patients
N/AUnknown

Survey on Menstrual Symptoms, Health Related Quality of Life and Work Productivity in Patients Suffering From Pain During Menstruation (Dysmenorrhea) in Japan

Start: Sep 2020Est. completion: Jun 2021397 patients
N/ACompleted
NCT03230994UNION therapeuticsCooperative Adenomyosis Network

Cooperative Adenomyosis Network

Start: Jun 2017Est. completion: Dec 20205,000 patients
N/AUnknown
NCT01449305Enterprise TherapeuticsNanoone Woman Underwear

Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea

Start: Oct 2011Est. completion: Jun 201244 patients
N/ACompleted

YAZ Post-marketing Surveillance in Japan

Start: Jun 2011Est. completion: Mar 20183,273 patients
N/ACompleted

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Start: Jan 2010Est. completion: Dec 2010176 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 11,689 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.